AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9988396 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test (OGTT)
Number of subjects: 70
Study 7771479 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria and macroalbuminuria
Number of subjects: 933
Study 2178521 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 6 mg
Number of subjects: 221
Study 2178521 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg
Number of subjects: 221
Study 2178521 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (all doses)
Number of subjects: 221
Study 2178521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 6945911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (VND)
Number of subjects: 179
Study 6945911 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (VCR)
Number of subjects: 179
Study 6945911 — intervention group
Group type: EXPERIMENTAL
Intervention: First relapsers (both VND and VCR)
Number of subjects: 179
Study 6945911 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent relapsers (both VND and VCR)
Number of subjects: 179
Study 30880443 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam (25 mg, 50 mg)
Number of subjects: 7595
Study 30880443 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam
Number of subjects: 7595
Study 30880443 — intervention group
Group type: COMPARATOR
Intervention: placebo or active control
Number of subjects: 7595
Study 28658202 — intervention group
Group type: EXPERIMENTAL
Intervention: TacHexal
Number of subjects: 0
Study 28658202 — intervention group
Group type: COMPARATOR
Intervention: Prograf
Number of subjects: 0
Study 26496519 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS Program
Number of subjects: 34
Study 24617776 — intervention group
Group type: EXPERIMENTAL
Intervention: Social comparison intervention (20 min computer-tailored interview in audio format)
Number of subjects: 150
Study 24617776 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control condition)
Number of subjects: 150
Study 22281416 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible(MIB) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Number of subjects: 1864
Study 22281416 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible(APC) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Number of subjects: 1864
Study 22281416 — intervention group
Group type: COMPARATOR
Intervention: Conventional 24/4 regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Number of subjects: 1864
Study 20658805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 308
Study 20658805 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 308
Study 20658805 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy only
Number of subjects: 308
Study 20658805 — intervention group
Group type: COMPARATOR
Intervention: Written Accounts
Number of subjects: 308
Study 17967671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency/low-volume ventilation with 100% oxygen (group 1)
Number of subjects: 50
Study 17967671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency/low-volume ventilation with 21% oxygen (group 2)
Number of subjects: 50
Study 17967671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure of 5 cm H(2)O with 100% oxygen (group 3)
Number of subjects: 50
Study 17967671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure of 5 cm H(2)O with 21% oxygen (group 4)
Number of subjects: 50
Study 17967671 — intervention group
Group type: COMPARATOR
Intervention: Passive deflation (group 5)
Number of subjects: 50
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-based regimens
Number of subjects: 0
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/tenofovir
Number of subjects: 0
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine/lamivudine/tenofovir
Number of subjects: 0
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine-containing treatment
Number of subjects: 0
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily abacavir regimens
Number of subjects: 0
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily lopinavir/ritonavir regimens
Number of subjects: 0
Study 15310939 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 400 mg/tenofovir regimens
Number of subjects: 0
Study 12437764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 3577
Study 12437764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study 9604358 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise bursts
Number of subjects: 0
Study 9604358 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-modulated tones
Number of subjects: 0
Study 9604358 — intervention group
Group type: EXPERIMENTAL
Intervention: Trains of short noise bursts
Number of subjects: 0
Study 9604358 — intervention group
Group type: COMPARATOR
Intervention: Control for azimuth response components
Number of subjects: 0
Study 8553146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg buserelin
Number of subjects: 32
Study 8553146 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mg buserelin
Number of subjects: 32
Study 8553146 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 mg buserelin
Number of subjects: 32
Study 2700103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg in a single morning dose
Number of subjects: 55
Study 2700103 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg in a single nocte dose
Number of subjects: 55
Study 797044 — intervention group
Group type: EXPERIMENTAL
Intervention: delta1-tetrahydrocannabinol (THC) 200 mug in ethanol
Number of subjects: 10
Study 797044 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 100 mug (Ventolin inhaler)
Number of subjects: 10
Study 797044 — intervention group
Group type: COMPARATOR
Intervention: placebo-ethanol only
Number of subjects: 10
Study 31323454 — intervention group
Group type: EXPERIMENTAL
Intervention: CADScor®System (Acarix A/S, Denmark)
Number of subjects: 2000
Study 31323454 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T cardiac magnetic resonance imaging (3T CMRI)
Number of subjects: 2000
Study 31323454 — intervention group
Group type: EXPERIMENTAL
Intervention: 82rubidium positron emission tomography (82Rb-PET)
Number of subjects: 2000
Study 31323454 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-derived fractional flow reserve (FFRCT)
Number of subjects: 2000
Study 31323454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 2000
Study 31323454 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 2000
Study 28007635 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pharmaceutical care at a psychosocial intervention
Number of subjects: 240
Study 28007635 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 240
Study 28007635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 26653621 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery stent placement plus medical therapy
Number of subjects: 947
Study 26653621 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 947
Study 22485012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 157
Study 22485012 — intervention group
Group type: COMPARATOR
Intervention: Text pamphlet
Number of subjects: 157
Study 22207522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC) (2 × 1) for 4 weeks
Number of subjects: 42
Study 22207522 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine/timolol fixed combination (BTFC) (2 × 1) for 4 weeks
Number of subjects: 42
Study 22207522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTFC and BTFC
Number of subjects: 42
Study 22207522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 42
Study 19630975 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized treatment based on active and passive joint repositioning, stabilization exercises, stretching of the periarticular shoulder muscles and postural reeducation.
Number of subjects: 0
Study 19630975 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized treatment with the addition of dry needling applied to active MTrPs.
Number of subjects: 0
Study 16485577 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding levothyroxine before 131I therapy (Group G1.1)
Number of subjects: 163
Study 16485577 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding levothyroxine before 131I therapy (Group G1.2)
Number of subjects: 163
Study 16485577 — intervention group
Group type: COMPARATOR
Intervention: Administration of recombinant human thyrotropin without stopping levothyroxine (Group G2)
Number of subjects: 163
Study 15277271 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 38-3441 at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule)
Number of subjects: 81
Study 15277271 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 38-3441 at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule)
Number of subjects: 81
Study 15277271 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 38-3441
Number of subjects: 81
Study 11160951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day target maintenance dosage, adjusted from 100 to 500 mg/day)
Number of subjects: 133
Study 11160951 — intervention group
Group type: COMPARATOR
Intervention: Valproate (20 mg/kg/day target maintenance dosage, adjusted from 10 to 60 mg/kg/day)
Number of subjects: 133
Study 11160951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 133
Study 11160951 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 133
Study 9037288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sachse urethrotomy
Number of subjects: 80
Study 9037288 — intervention group
Group type: COMPARATOR
Intervention: Guillemin's technique (double direct-optical endoscopic urethrotomy plus transurethral resection of scar tissues)
Number of subjects: 80
Study 8287887 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy + Cyproterone Acetate (CPA)
Number of subjects: 294
Study 8287887 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy + Placebo
Number of subjects: 294
Study 2887431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 10
Study 2887431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 10
Study 2887431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 10
Study 2887431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31529097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 18
Study 30519590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast administration of 500ml balanced crystalloid fluid challenge (5-10 minutes)
Number of subjects: 66
Study 30519590 — intervention group
Group type: COMPARATOR
Intervention: Slow administration of 500ml balanced crystalloid fluid challenge (20-30 minutes)
Number of subjects: 66
Study 30519590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast administration
Number of subjects: 66
Study 30519590 — intervention group
Group type: COMPARATOR
Intervention: Slow administration
Number of subjects: 66
Study 27716095 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly Persons in the Risk Zone (EPRZ) health-promoting programme
Number of subjects: 459
Study 27716095 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 459
Study 24126707 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 582
Study 24126707 — intervention group
Group type: COMPARATOR
Intervention: methadone
Number of subjects: 582
Study 22237884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic-containing formula (PRE)
Number of subjects: 100
Study 22237884 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CON)
Number of subjects: 100
Study 22237884 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 100
Study 22237884 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants (FF)
Number of subjects: 100
Study 20831535 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (RAC)
Number of subjects: 0
Study 20831535 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (EAC)
Number of subjects: 0
Study 20831535 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-sensitive strains
Number of subjects: 0
Study 19024254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CHX varnish applied once (Group A)
Number of subjects: 55
Study 19024254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CHX varnish applied once daily for 3 consecutive days (Group B)
Number of subjects: 55
Study 19024254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CHX varnish applied three times with 4 days interval (Group C)
Number of subjects: 55
Study 19024254 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish applied once daily for 3 consecutive days (Group D)
Number of subjects: 55
Study 16458191 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenolic content olive oil (366 mg/kg)
Number of subjects: 12
Study 16458191 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate phenolic content olive oil (164 mg/kg)
Number of subjects: 12
Study 16458191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phenolic content olive oil (2.7 mg/kg)
Number of subjects: 12
Study 15152880 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Construct Tailoring (BCT)
Number of subjects: 1227
Study 15152880 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Relevant Tailoring (CRT)
Number of subjects: 1227
Study 15152880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (BCT + CRT)
Number of subjects: 1227
Study 11309548 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg total: 20 mg on days 0 and 4)
Number of subjects: 184
Study 9339962 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists, antacids, sucralfate, pirenzepine
Number of subjects: 0
Study 9339962 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 0
Study 9339962 — intervention group
Group type: EXPERIMENTAL
Intervention: prostaglandins, omeprazole
Number of subjects: 0
Study 9339962 — intervention group
Group type: EXPERIMENTAL
Intervention: optimised resuscitation and ICU regime
Number of subjects: 0
Study 8373288 — intervention group
Group type: EXPERIMENTAL
Intervention: Double method wash
Number of subjects: 195
Study 8373288 — intervention group
Group type: COMPARATOR
Intervention: Centrifuge method wash
Number of subjects: 195
Study 3728212 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (intravenous administration for 5 hours)
Number of subjects: 5
Study 3728212 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (intravenous administration for 5 hours)
Number of subjects: 5
Study 3728212 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (oral administration for 24 days)
Number of subjects: 5
Study 30834639 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agent first
Number of subjects: 562
Study 30834639 — intervention group
Group type: COMPARATOR
Intervention: Sedative agent first
Number of subjects: 562
Study 29652786 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (standard decompressive laminectomy with or without fusion)
Number of subjects: 69
Study 29652786 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 69
Study 25565290 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led integrated diabetes care
Number of subjects: 30
Study 25289885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-m cycling time trial at 6 pm
Number of subjects: 9
Study 25289885 — intervention group
Group type: COMPARATOR
Intervention: 1000-m cycling time trial at 8 am
Number of subjects: 9
Study 25289885 — intervention group
Group type: COMPARATOR
Intervention: Hormonal response in the morning
Number of subjects: 9
Study 25289885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal response in the evening
Number of subjects: 9
Study 25289885 — intervention group
Group type: COMPARATOR
Intervention: Plasma glucose in the morning
Number of subjects: 9
Study 25289885 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine response in the morning
Number of subjects: 9
Study 25289885 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine response in the evening
Number of subjects: 9
Study 25289885 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle recruitment measured by electromyography
Number of subjects: 9
Study 22301799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-tolerable plasma (TTP)
Number of subjects: 0
Study 22301799 — intervention group
Group type: COMPARATOR
Intervention: Octenidine hydrochloride with 2-phenoxyethanol
Number of subjects: 0
Study 20140897 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g isomaltulose
Number of subjects: 24
Study 20140897 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g sucrose
Number of subjects: 24
Study 20140897 — intervention group
Group type: COMPARATOR
Intervention: water control
Number of subjects: 24
Study 17650803 — intervention group
Group type: EXPERIMENTAL
Intervention: RT combined with oral TCM from the start of RT till 5 weeks after RT
Number of subjects: 195
Study 17650803 — intervention group
Group type: COMPARATOR
Intervention: RT alone for 7 weeks
Number of subjects: 195
Study 15249999 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) for cup placement in THA
Number of subjects: 185
Study 15249999 — intervention group
Group type: COMPARATOR
Intervention: Free-hand cup placement in THA
Number of subjects: 185
Study 12462555 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.1 microg/kg min)
Number of subjects: 25
Study 12462555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg min)
Number of subjects: 25
Study 12462555 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 25
Study 9430135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acid mixture devoid of tryptophan)
Number of subjects: 12
Study 9430135 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (amino acid mixture containing 2.3 g of tryptophan)
Number of subjects: 12
Study 7655769 — intervention group
Group type: EXPERIMENTAL
Intervention: Profinal (600 mg)
Number of subjects: 18
Study 7655769 — intervention group
Group type: COMPARATOR
Intervention: Brufen (600 mg)
Number of subjects: 18
Study 2571061 — intervention group
Group type: EXPERIMENTAL
Intervention: OM756 alpha 10 mg propranolol 'Inderal' tablet
Number of subjects: 12
Study 2571061 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic 10 mg propranolol tablet
Number of subjects: 12
Study 2571061 — intervention group
Group type: COMPARATOR
Intervention: Generic placebo
Number of subjects: 12
Study 1099176 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 mg of ascorbic acid administered 27 and 3 hours prior to assessment
Number of subjects: 18
Study 1099176 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of ascorbic acid administered in the same manner
Number of subjects: 18
Study 29985968 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls on the Move (GOTM) intervention
Number of subjects: 1519
Study 29985968 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1519
Study 27940187 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted DESTRESS intervention
Number of subjects: 0
Study 27940187 — intervention group
Group type: COMPARATOR
Intervention: Telephone monitoring only (Control)
Number of subjects: 0
Study 25982993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 10
Study 23065145 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir (TFV)
Number of subjects: 144
Study 23065145 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily topical tenofovir (TFV) vaginal gel
Number of subjects: 144
Study 23065145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral tablet and vaginal gel
Number of subjects: 144
Study 23065145 — intervention group
Group type: COMPARATOR
Intervention: Oral tablet
Number of subjects: 144
Study 23065145 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gel
Number of subjects: 144
Study 21617526 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard endotracheal intubation (ETI)
Number of subjects: 42
Study 21617526 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 42
Study 21617526 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 42
Study 19877969 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 351
Study 19877969 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 351
Study 16449754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor treatment (AD+ChEI)
Number of subjects: 28
Study 16449754 — intervention group
Group type: COMPARATOR
Intervention: No Cholinesterase inhibitor treatment (AD‐ChEI)
Number of subjects: 28
Study 15339677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 200
Study 15339677 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 200
Study 15339677 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 200
Study 15339677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse cytogenetics and white blood cell count ≥20 yen 10^9/L at diagnosis
Number of subjects: 200
Study 11278221 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 132
Study 11278221 — intervention group
Group type: COMPARATOR
Intervention: IVF in unstimulated cycles
Number of subjects: 132